Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.59 |
| ▸ | CTSA | P10619 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.44 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.44 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.44 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.44 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151189 | 0.86 | RXRA (0.58) | BCAT2CTSARXRARXRBRXRG | |
| SCHEMBL28025564 | 0.84 | RXRA (0.51) | BCAT2CTSARXRARXRBRXRG | |
| SCHEMBL10908563 | 0.83 | BCAT2 (0.77) | BCAT2CTSAKEAP1NFE2L2CHEK1 | |
| SCHEMBL2563193 | 0.82 | BCAT2 (0.65) | BCAT2CTSAKEAP1NFE2L2CHEK1 | |
| SCHEMBL19697976 | 0.81 | BCAT2 (0.50) | BCAT2CTSAKEAP1NFE2L2CHEK1 | |
| SCHEMBL24721247 | 0.79 | PTPN5 (0.48) | RXRARXRBRXRGNR4A2ALOX5AP | |
| SCHEMBL9177215 | 0.79 | RXRA (0.50) | RXRARXRBRXRGNR4A2PTPN5 | |
| SCHEMBL16149659 | 0.79 | BCAT2 (0.91) | BCAT2KEAP1NFE2L2CHEK1NPC1 | |
| SCHEMBL6667275 | 0.79 | BCAT2 (0.65) | BCAT2CTSAKEAP1NFE2L2CHEK1 | |
| SCHEMBL27958761 | 0.79 | RXRA (0.43) | CTSARXRARXRBRXRGFADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | BCAT2 2484/4885CTSA 4365/4885RXRA 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.